Published in Gene Therapy Weekly, July 20th, 2006
"IL-12 has potential as an immunotherapeutic agent for the treatment of cancer but is unfortunately associated with toxicity. Delivery of a plasmid encoding IL-12 with electroporation induces an antitumor effect in the B16 mouse melanoma model without serious side effects," wrote L. Heller and colleagues, University of South Florida.
They continued that the study was done "to translate this observation to the clinic, an evaluation of toxicity was done in the mouse model."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.